1. Home
  2. BXSL vs DNTH Comparison

BXSL vs DNTH Comparison

Compare BXSL & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Secured Lending Fund of Beneficial Interest

BXSL

Blackstone Secured Lending Fund of Beneficial Interest

N/A

Current Price

$23.93

Market Cap

5.7B

Sector

Finance

ML Signal

N/A

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

N/A

Current Price

$89.30

Market Cap

5.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BXSL
DNTH
Founded
2018
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
5.9B
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
BXSL
DNTH
Price
$23.93
$89.30
Analyst Decision
Hold
Strong Buy
Analyst Count
12
16
Target Price
$24.66
★ $140.80
AVG Volume (30 Days)
★ 1.2M
660.0K
Earning Date
11-09-2026
11-04-2026
Dividend Yield
★ 12.84%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.15
N/A
Revenue
N/A
★ $2,036,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$159.33
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$22.47
$32.28
52 Week High
$28.59
$117.88

Technical Indicators

Market Signals
Indicator
BXSL
DNTH
Relative Strength Index (RSI) 38.82 35.61
Support Level $23.26 $89.21
Resistance Level $25.00 $91.04
Average True Range (ATR) 0.35 4.60
MACD -0.12 -1.13
Stochastic Oscillator 8.85 23.83

Price Performance

Historical Comparison
BXSL
DNTH

About BXSL Blackstone Secured Lending Fund of Beneficial Interest

Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: